Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

导出原文传递

翻译打印收藏纠错

作者： Smolen, Josef S. ^[1] ; Kremer, Joel M. ^[2] ; Gaich, Carol L. ^[3] ; DeLozier, Amy M. ^[4] ; Schlichting, Douglas E. ^[5] ; Xie, Li ^[6] ; Stoykov, Ivaylo ^[7] ; Rooney, Terence ; Bird, Paul ; Sanchez Burson, Juan Miguel ; Genovese, Mark C. ; Combe, Bernard

作者单位： Med Univ Vienna, Vienna, Austria ^[1] Univ New South Wales, Sydney, NSW, Australia ^[2] Univ Montpellier, Lapeyronie Hosp, Montpellier, France ^[3] Valme Univ Hosp, Div Rheumatol, Seville, Spain ^[4] Eli Lilly & Co, Indianapolis, IN 46285 USA ^[5] Albany Med Coll, Albany, NY 12208 USA ^[6] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA ^[7]

发布时间 2017-12-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Annals of the Rheumatic Diseases

2017年76卷4期

694-700页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

Annals of the Rheumatic Diseases

相似文献

Annals of the Rheumatic Diseases

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

Annals of the Rheumatic Diseases

相似文献

Annals of the Rheumatic Diseases

相关期刊

检索历史清除